ArticleOncology letters2013
In vivo evaluation of the synthesized novel 2-benzyloxybenzaldehyde analog CCY-1a-E2 for the treatment of leukemia in the BALB/c mouse WEHI-3 allograft model.
Article in Oncology letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Leukemia growth is inhibited by benzoxime without causing any harmful effect in rats bearing RBL-1 ×enotransplants.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our previous study demonstrated that the 2-benzyloxybenzaldehyde analog CCY-1a-E2 is a potent compound against HL-60 human leukemia cell lines. To investigate the potential therapeutic application of CCY-1a-E2 for leukemia, we analyzed the antileukemic effects and safety of CCY-1a-E2 in the BALB/c mouse WEHI-3 allograft model. Our results showed that CCY-1a-E2 decreased the percentage of viable cells in a concentration-dependent manner. The IC(50) of CCY-1a-E2 was 5 μM for the 24-h treatment of WEHI-3 cells. We examined the antileukemic activity of CCY-1a-E2 in the BALB/c mouse WEHI-3 allograft model. The CCY-1a-E2 (100 mg/kg) group was not found to have significantly decreased body weight compared with the control group, while the leukemia group was found to have significantly decreased body weight compared with the control mice. The CCY-1a-E2 (100 mg/kg) group showed no difference in spleen and liver weight, but significantly decreased levels of CD11b and CD45 compared with the leukemia group. In safety evaluation analysis, CCY-1a-E2 had no adverse effects on renal, hepatic and hematological parameters. Based on these observations, CCY-1a-E2 has efficacious antileukemic activity in the BALB/c mouse WEHI-3 allograft model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.